Literature DB >> 11762804

Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited.

J T Tamsma1, H J Keizer, A E Meinders.   

Abstract

Peritonitis carcinomatosa, indicating the presence of malignant cells in the peritoneal cavity, is a well-known complication of malignant disease. As a result, so-called malignant ascites develops. Malignant ascites is a debilitating condition for which no effective anti-tumor therapy is available. Frequent draining may be necessary to relieve pain and discomfort. Most studies regarding malignant ascites focus on diagnosis and treatment. In this paper. we will address the subject from a pathophysiologic perspective, using the characteristics of malignant ascites, Starling's equation of capillary forces, and recent knowledge regarding biologically active peptides produced by tumor cells. Following this approach. apart from decreased lymphatic ascites absorption, increased net capillary fluid-production can be identified as a contributing feature of ascites formation. The increased net filtration is due to an increase of overall capillary membrane-surface, increased capillary permeability and a subsequent increase of intraperitoneal protein concentration leading to increased intraperitoneal oncotic pressure. This sequence might be the result of biologically active peptides produced by tumor cells such as vascular endothelial growth factor and basic fibroblast growth factor. Interference with these mediators may serve as a target in future therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762804     DOI: 10.1023/a:1012504904713

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

Review 1.  Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.

Authors:  Vathany Kulasingam; Maria P Pavlou; Eleftherios P Diamandis
Journal:  Nat Rev Cancer       Date:  2010-04-12       Impact factor: 60.716

2.  Respiratory distress due to malignant ascites palliated by hyperthermic intraperitoneal chemotherapy.

Authors:  Marijn Marinus Leonardus van den Houten; Thijs Ralf van Oudheusden; Michael Derek Philip Luyer; Simon Willem Nienhuijs; Ignace Hubertus Johannes Theodorus de Hingh
Journal:  World J Gastrointest Surg       Date:  2015-03-27

3.  Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.

Authors:  Hui Zhao; Xiaosong Li; Dianjun Chen; Jianhua Cai; Yan Fu; Huanrong Kang; Jie Gao; Ke Gao; Nan Du
Journal:  Med Oncol       Date:  2015-01-22       Impact factor: 3.064

4.  Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.

Authors:  Matteo Bonatti; Riccardo Valletta; Giulia A Zamboni; Fabio Lombardo; Maria Senoner; Mariachiara Simioni; Guenther Schifferle; Giampietro Bonatti
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

Review 5.  Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Authors:  Filippo Bellati; Chiara Napoletano; Ilary Ruscito; Maria Pastore; Milena Pernice; Morena Antonilli; Marianna Nuti; Pierluigi Benedetti Panici
Journal:  Invest New Drugs       Date:  2009-11-24       Impact factor: 3.850

6.  Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Authors:  Cynthia Kuk; Vathany Kulasingam; C Geeth Gunawardana; Chris R Smith; Ihor Batruch; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-01       Impact factor: 5.911

7.  Detection of type IV collagenase activity in malignant ascites.

Authors:  Xiao-Min Sun; Wei-Guo Dong; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

8.  Role of VEGF and CD44v6 in differentiating benign from malignant ascites.

Authors:  Wei-Guo Dong; Xiao-Min Sun; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options.

Authors:  Yvonne L B Klaver; Valery E P P Lemmens; Simon W Nienhuijs; Misha D P Luyer; Ignace H J T de Hingh
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

10.  Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model.

Authors:  Zi-Yu Jiang; Shu-Kui Qin; Xiao-Jin Yin; Ya-Li Chen; Lin Zhu
Journal:  Exp Ther Med       Date:  2012-05-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.